Document is current
Any future updates will be listed below
-
Authors
Song, Zhengbo
Lou, Guangyuan
Wang, Yina
Yang, Zhiping
Wang, Wenxian
Ji, Yongling
Chen, Shiqing
Xu, Chunwei
Hu, Xiao
Zhang, Yiping http://orcid.org/0000-0001-7039-4226
- License Information
-
More Information
Article History
Received: 18 January 2022
Accepted: 29 March 2022
First Online: 10 May 2022
Declarations
:
: The study protocol (No. IRB-2017-13) was approved by the institutional ethics committee of Zhejiang Cancer Hospital, the institutional ethics committee of The First Affiliated Hospital, College of Medicine, Zhejiang University, and the institutional ethics committee of The First Hospital of Jiaxing, in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was provided by each patient before the onset of any trial-related treatment.
: Not applicable.
: SC is an employee of 3D Medicines Inc. The remaining authors declare no competing of interests.
